Trastuzumab was approved for treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.